/HROW
HROW Stock - Harrow Health, Inc.
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$46.40+4.13%
+$1.84 (+4.13%) • Dec 19
89
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.97
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+63.8%upside
Target: $76.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for HROW
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$45.94 – $46.86
TARGET (TP)$76.00
STOP LOSS$42.69
RISK/REWARD1:8.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.07
52W High$51.30
52W Low$20.85
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $199.61M | $130.19M | $88.59M | $72.48M | $48.87M |
| Gross Profit | $150.37M | $90.55M | $63.21M | $54.26M | $34.41M |
| Gross Margin | 75.3% | 69.6% | 71.3% | 74.9% | 70.4% |
| Operating Income | $8.82M | $431,000 | $1.92M | $1.61M | $385,000 |
| Net Income | $-17,481,000 | $-24,411,000 | $-14,086,000 | $-18,007,000 | $-3,357,000 |
| Net Margin | -8.8% | -18.7% | -15.9% | -24.8% | -6.9% |
| EPS | $-0.49 | $-0.75 | $-0.51 | $-0.69 | $-0.13 |
Company Overview
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
6 Bullish0 Neutral/Bearish
Price Targets
$51
Average Target
↑ 9.6% Upside
Now
$17
Low
$51
Average
$76
High
Based on 6 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 11th 2025 | Cantor Fitzgerald | Initiation | Overweight | $76 |
| June 12th 2025 | BTIG Research | Initiation | Buy | $62 |
| June 10th 2025 | William Blair | Initiation | Outperform | - |
| February 6th 2025 | H.C. Wainwright | Initiation | Buy | $57 |
| December 4th 2024 | B. Riley Securities | Reiterated | Buy | $69← $73 |
| April 11th 2024 | Craig Hallum | Initiation | Buy | $24 |
| September 8th 2022 | B. Riley Securities | Resumed | Buy | $17 |
Earnings History & Surprises
HROWBeat Rate
50%
Last 18 quarters
Avg Surprise
-441.7%
EPS vs Estimate
Beats / Misses
9/9
Last 12 quarters
Latest EPS
$0.33
Q4 2025
EPS Surprise History
Q1 24
-455.6%
$-0.27vs$-0.05
Q2 24
-12.0%
$-0.28vs$-0.25
Q3 24
+48.0%
$-0.13vs$-0.25
Q4 24
-140.0%
$-0.12vs$-0.05
Q1 25
+127.3%
$0.25vs$0.11
Q2 25
-2000.0%
$-0.38vs$0.02
Q3 25
-23.4%
$0.24vs$0.31
Q4 25
+50.0%
$0.33vs$0.22
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 26, 2026 | $0.45 | — | — | — |
Q1 2026 | Mar 16, 2026 | — | — | — | — |
Q4 2025 | Nov 10, 2025 | $0.22 | $0.33 | +50.0% | ✓ BEAT |
Q3 2025 | Aug 11, 2025 | $0.31 | $0.24 | -23.4% | ✗ MISS |
Q2 2025 | May 8, 2025 | $0.02 | $-0.38 | -2000.0% | ✗ MISS |
Q1 2025 | Mar 27, 2025 | $0.11 | $0.25 | +127.3% | ✓ BEAT |
Q4 2024 | Nov 13, 2024 | $-0.05 | $-0.12 | -140.0% | ✗ MISS |
Q3 2024 | Aug 7, 2024 | $-0.25 | $-0.13 | +48.0% | ✓ BEAT |
Q2 2024 | May 13, 2024 | $-0.25 | $-0.28 | -12.0% | ✗ MISS |
Q1 2024 | Mar 19, 2024 | $-0.05 | $-0.27 | -455.6% | ✗ MISS |
Q4 2023 | Nov 13, 2023 | $-0.02 | $-0.09 | -467.8% | ✗ MISS |
Q3 2023 | Aug 9, 2023 | $-0.01 | $-0.02 | -250.3% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-0.06 | $-0.03 | +50.0% | ✓ BEAT |
Q1 2023 | Mar 23, 2023 | $-0.15 | $0.07 | +146.7% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-0.00 | $-0.06 | -9577.4% | ✗ MISS |
Q3 2022 | Aug 9, 2022 | $-0.00 | $0.01 | +3325.8% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $0.01 | $0.03 | +185.7% | ✓ BEAT |
Q1 2022 | Mar 10, 2022 | $0.08 | $-0.01 | -112.5% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-0.00 | $0.05 | +1139.5% | ✓ BEAT |
Q3 2021 | Aug 10, 2021 | $-0.13 | $-0.11 | +15.4% | ✓ BEAT |
Latest News
Ladenburg Thalmann Maintains Buy on Harrow, Raises Price Target to $66
📈 PositiveBenzinga•Nov 12, 2025, 07:48 PM
HC Wainwright & Co. Maintains Buy on Harrow, Raises Price Target to $69
📈 PositiveBenzinga•Nov 12, 2025, 11:44 AM
CORRECTION: Harrow Q3 Adj. EPS $0.33 Beats $0.26 Estimate, Sales $71.638M Miss $73.705M Estimate
➖ NeutralBenzinga•Nov 10, 2025, 11:00 PM
Harrow Sees FY2025 Sales $270.000M-$280.000M vs $281.647M Est
📉 NegativeBenzinga•Nov 10, 2025, 09:24 PM
Harrow shares are trading lower after the company reported worse-than-expected Q3 financial results.
📉 NegativeBenzinga•Nov 10, 2025, 09:16 PM
Harrow Q3 Adj. EPS $(0.12) Misses $0.26 Estimate, Sales $71.638M Miss $73.705M Estimate
📉 NegativeBenzinga•Nov 10, 2025, 09:12 PM
B. Riley Securities Reiterates Buy on Harrow, Raises Price Target to $74
📈 PositiveBenzinga•Oct 1, 2025, 02:40 PM
Lake Street Maintains Buy on Harrow, Raises Price Target to $70
📈 PositiveBenzinga•Sep 29, 2025, 02:32 PM
HC Wainwright & Co. Reiterates Buy on Harrow, Maintains $64 Price Target
📈 PositiveBenzinga•Sep 29, 2025, 10:27 AM
BTIG Reiterates Buy on Harrow, Maintains $63 Price Target
📈 PositiveBenzinga•Sep 29, 2025, 10:06 AM
Harrow shares are trading higher after the company announced it will acquire Melt Pharma.
📈 PositiveBenzinga•Sep 26, 2025, 04:27 PM
Harrow To Acquire Melt Pharma, Advancing Sublingual Sedation Therapy MELT-300 Toward 2027 NDA After Positive Phase 3 Results
📈 PositiveBenzinga•Sep 26, 2025, 11:03 AM
B. Riley Securities Maintains Buy on Harrow, Raises Price Target to $70
📈 PositiveBenzinga•Sep 23, 2025, 05:50 PM
Craig-Hallum Maintains Buy on Harrow, Raises Price Target to $64
📈 PositiveBenzinga•Sep 23, 2025, 01:51 PM
Harrow jumps as Cantor initiates with Bullish view on conservative outlook
📈 PositiveSeeking Alpha•Jul 11, 2025, 02:44 PM
Frequently Asked Questions about HROW
What is HROW's current stock price?
Harrow Health, Inc. (HROW) is currently trading at $46.40 per share. The stock has moved +4.13% today.
What is the analyst price target for HROW?
The average analyst price target for HROW is $76.00, based on 1 analyst.
What sector is Harrow Health, Inc. in?
Harrow Health, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is HROW's market cap?
Harrow Health, Inc. has a market capitalization of $1.72 billion, making it a small-cap company.
Does HROW pay dividends?
No, Harrow Health, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALVO
Alvotech
$4.90
Mkt Cap: $1.5B
AMPH
Amphastar Pharmaceuticals, Inc.
$26.60
Mkt Cap: $1.2B
BLFS
BioLife Solutions, Inc.
$25.07
Mkt Cap: $1.2B
COLL
Collegium Pharmaceutical, Inc.
$48.88
Mkt Cap: $1.5B
DVAX
Dynavax Technologies Corporation
$10.86
Mkt Cap: $1.3B
EVO
Evotec SE
$2.95
Mkt Cap: $1.0B
KMTS
KESTRA MEDICAL TECHNOLOGIES, LTD.
$27.32
Mkt Cap: $1.6B
PHR
Phreesia, Inc.
$16.55
Mkt Cap: $1.0B
TLRY
Tilray Brands, Inc.
$11.16
Mkt Cap: $1.2B
TRVI
Trevi Therapeutics, Inc.
$13.01
Mkt Cap: $1.7B
Explore stocks similar to HROW for comparison